{"id":"ald403","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Upper respiratory tract infection"}]},"_chembl":{"chemblId":"CHEMBL3833320","moleculeType":"Antibody"},"_fixedAt":"2026-03-30T16:10:05.347697","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CGRP is released during migraine attacks and contributes to vasodilation, neurogenic inflammation, and pain signal transmission. By binding to and neutralizing CGRP, ALD403 prevents its interaction with CGRP receptors on neurons and blood vessels, thereby reducing migraine frequency and severity. This mechanism has demonstrated efficacy in preventing both episodic and chronic migraines.","oneSentence":"ALD403 is a monoclonal antibody that blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:00:33.798Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Eptinezumab","title":"Eptinezumab","extract":"Eptinezumab, sold under the brand name Vyepti, is a medication used for the preventive treatment of migraine in adults. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta. It is administered by intravenous infusion."},"indications":{"approved":[{"name":"Migraine prevention (episodic and chronic)"}]},"_fixedFields":["sideEffects"],"trialDetails":[{"nctId":"NCT05635604","phase":"NA","title":"Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients.","status":"COMPLETED","sponsor":"Danish Headache Center","startDate":"2023-03-01","conditions":"Migraine","enrollment":38},{"nctId":"NCT02974153","phase":"PHASE3","title":"Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine","status":"COMPLETED","sponsor":"Alder Biopharmaceuticals, Inc.","startDate":"2016-11","conditions":"Migraine Disorders","enrollment":1121},{"nctId":"NCT02559895","phase":"PHASE3","title":"A Multicenter Assessment of ALD403 in Frequent Episodic Migraine","status":"COMPLETED","sponsor":"Alder Biopharmaceuticals, Inc.","startDate":"2015-09","conditions":"Migraine Disorders","enrollment":898},{"nctId":"NCT02985398","phase":"PHASE3","title":"An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine","status":"COMPLETED","sponsor":"Alder Biopharmaceuticals, Inc.","startDate":"2016-12","conditions":"Migraine Disorder","enrollment":128},{"nctId":"NCT02275117","phase":"PHASE2","title":"A Multicenter Assessment of ALD403 in Chronic Migraine","status":"COMPLETED","sponsor":"Alder Biopharmaceuticals, Inc.","startDate":"2014-10","conditions":"Migraine Disorders","enrollment":665},{"nctId":"NCT01772524","phase":"PHASE1","title":"Safety, Efficacy and Pharmacokinetics of ALD403","status":"COMPLETED","sponsor":"Alder Biopharmaceuticals, Inc.","startDate":"2013-01","conditions":"Migraine","enrollment":163},{"nctId":"NCT01579383","phase":"PHASE1","title":"Safety Tolerability and Pharmacokinetics of ALD403","status":"COMPLETED","sponsor":"Alder Biopharmaceuticals, Inc.","startDate":"2012-04","conditions":"Migraine Disorders","enrollment":104}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Eptinezumab-jjmr","Vyepti"],"phase":"phase_3","status":"active","brandName":"ALD403","genericName":"ALD403","companyName":"Alder Biopharmaceuticals, Inc.","companyId":"alder-biopharmaceuticals-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"ALD403 is a monoclonal antibody that blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis. Used for Migraine prevention (episodic and chronic).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}